Kbc Group Nv Alkermes Plc. Transaction History
Kbc Group Nv
- $33.1 Billion
- Q3 2024
A detailed history of Kbc Group Nv transactions in Alkermes Plc. stock. As of the latest transaction made, Kbc Group Nv holds 4,890 shares of ALKS stock, worth $137,311. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,890
Previous 4,116
18.8%
Holding current value
$137,311
Previous $99,000
38.38%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ALKS
# of Institutions
364Shares Held
181MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$817 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$533 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$365 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$355 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$258 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.61B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...